NCT00615901 - Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions

Breast Cancer

Interventions

DRUG

cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim

C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 P (PEG-filgrastim ) 6 mg. Eight doses of CMF q 14 days with PEG-filgrastim administered approximately 24 hours after chemotherapy. Day 14, is also considered day 1 of the next cycle.

Trial Locations (5)

10065

Memorial Sloan-Kettering Cancer Center, New York

10591

Memoral Sloan-Kettering Cancer Center at Phelps, Sleepy Hollow

11570

Memorial Sloan-Kettering Cancer Center at Mercy, Rockville Centre

11725

Memorial Sloan-Kettering Cancer Center at Commack, Commack

07920

Memorial Sloan-Kettering at Basking Ridge, Basking Ridge